Island Pharmaceuticals Limited (ASX:ILA)

Australia flag Australia · Delayed Price · Currency is AUD
0.3550
-0.0050 (-1.39%)
Apr 20, 2026, 3:09 PM AEST
Market Cap104.93M +194.4%
Revenue (ttm)62.85K -84.3%
Net Income-7.20M
EPS-0.03
Shares Out295.58M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,657
Average Volume208,935
Open0.3600
Previous Close0.3600
Day's Range0.3550 - 0.3600
52-Week Range0.1200 - 0.6300
Beta0.13
RSI40.73
Earnings DateMay 26, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ILA
Full Company Profile

Financial Performance

In fiscal year 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.

Financial Statements